• Molecular NameTamoxifen
  • SynonymTamoxifen Citrate; Tamoxifene [INN-French]; Tamoxifeno [INN-Spanish]; Tamoxifenum [INN-Latin]; Trans-Tamoxifen
  • Weight371.524
  • Drugbank_IDDB00675
  • ACS_NO10540-29-1
  • Show 3D model
  • LogP (experiment)6.589
  • LogP (predicted, AB/LogP v2.0)6.37
  • pka8.85
  • LogD (pH=7, predicted)4.97
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-3.76
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors0
  • No.of HBond Acceptors2
  • No.of Rotatable Bonds8
  • TPSA12.47
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn antagonist of the estrogen receptor in breast tissue. It has been the standard endocrine (anti-estrogen) therapy for hormone-positive early breast cancer, although aromatase inhibitors have been proposed for postmenopausal women.
  • Absorption_value100.0
  • Absorption (description)N/A
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein binding98.0
  • Volume of distribution (VD)50~60 L/kg
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmHepatic (CYP3A4, 2C9 and 2D6). The major pathway of elimination, N-demethylation, is catalyzed by CYP3A.
  • Half life4~11 days
  • ExcretionFecal
  • Urinary Excretion<1
  • Clerance1.4 ml/min/kg
  • ToxicitySigns observed at the highest doses following studies to determine LD50 in animals were respiratory difficulties and convulsions.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A